Navigation Links
3SBio Inc. to Present at the Oppenheimer & Co. 6th Annual China Dragon Conference
Date:2/7/2012

SHENYANG, China, Feb. 7, 2012 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (NASDAQ: SSRX) ("3SBio"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that Dr. Jing Lou, chief executive officer, and Mr. Bo Tan, chief financial officer, will present at the Oppenheimer & Co. 6th Annual China Dragon Conference being held March 14-15, 2012 in New York City.

The accompanying slides will be available at www.3sbio.com under the investor relations section.

About 3SBio Inc.

3SBio is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China.  Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases.  With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX". Please see www.3SBio.com for more information.

Investor Contacts

Bo Tan
Chief Financial Officer
3SBio Inc.
Tel: + 86 24 2581-1820
ir@3SBio.com

Tom Folinsbee
Director of Investor Relations
3SBio Inc.
Tel: + 852 8191-6991
ir@3SBio.com


'/>"/>
SOURCE 3SBio Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. 3SBio Inc. Announces Results of Annual General Meeting
2. 3SBio and Isotechnika Pharma Announce Strategic Partnership to Develop and Commercialize Voclosporin in China
3. 3SBio Announces Investor Conference Schedule
4. 3SBio Announces Partial Conversion of Isotechnika Debenture
5. 3SBio Inc. Schedules Third Quarter 2010 Unaudited Financial Results
6. 3SBio Announces Conversion of Isotechnika Debenture
7. 3SBio Inc. Announces SFDA Approval of High-Dose EPIAO
8. 3SBio Inc. Schedules Unaudited Second Quarter 2011 Results
9. 3SBio Inc. Announces Unaudited Second Quarter and First Half 2011 Results
10. 3SBio Inc. to Hold 2011 Annual General Meeting on September 20, 2011
11. 3SBio Inc. Schedules Unaudited Third Quarter 2011 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... LONDON , February 10, 2016 ... 2016, which will be held at Victoria Park Plaza in ... host an informative seminar on technology and future advances for ... seminar, led by Lorna Graham , associate director of ... technology to keep up with new regulations and standards in ...
(Date:2/10/2016)... ATLANTA , Feb. 10, 2016  LexisNexis® ... and technology, today announced the launch of ... analytics solution that helps improve and optimize the ... evaluation of performance using severity-adjusted scores. By measuring ... a critical solution to deliver better outcomes, improve ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... biopharmaceutical company developing novel, clinical-stage therapies for sickle cell ... an underwritten public offering of 29,090,910 units at a ... unit consists of one share of the Company,s common ... the Company,s common stock at an exercise price of ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s 2016 Executive Forum, taking ... of the country’s top healthcare executives to share insights on transformational strategies to ... Forum is the provider-centric perspective, experience, expertise and strategy shared by the participants,” ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... Gout ... switch, and brings pain that is often severe, with intense swelling and redness. It ... than eight million people, but older adults are the most susceptible, according to the ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood ... exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric ... in their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% ... this challenge and learn more about the Goal Attainment Scale, Education Resources Inc. ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of ... , As the longest running and largest worker's compensation event in Ohio, ...
Breaking Medicine News(10 mins):